Scarica l'app Stockscreener
18.92
4.92%
-0.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viridian Therapeutics Market Sentiment - Benzinga España
Viridian Therapeutics Inc (VRDN) Institutional Confidence - TradingKey
Viridian Therapeutics Inc (VRDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viridian Therapeutics Inc (VRDN) Income Statement - TradingKey
Viridian Therapeutics Inc (VRDN) Balance Sheet - TradingKey
Viridian Therapeutics Inc (VRDN) Cash Flow - TradingKey
Viridian Therapeutics, Inc. Revenue Breakdown – NASDAQ:VRDN - TradingView
Viridian Therapeutics Inc (VRDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis - TradingKey
VRDN|Viridian Therapeutics Inc|Price:19.270|Chg%:+0.010 - TradingKey
VRDN|Viridian Therapeutics Inc|Price:19.965|Chg%:+0.695 - TradingKey
Viridian Therapeutics Inc (VRDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Viridian Therapeutics stock trades around recent lows as cash runway and thyroid eye trial data shap - Ad-hoc-news.de
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages - Ophthalmology Times Europe
VRDN|Viridian Therapeutics Inc|Price:19.247|Chg%:-0.013 - TradingKey
Price-Driven Insight from (VRDN) for Rule-Based Strategy - Stock Traders Daily
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics (VRDN) Stock Analysis: A Biotech Gem with Nearly 95% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary - Quartr
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich? - Yahoo Finance
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today - Yahoo Finance
VRDN6389238 Bond Coupon Profile — Rate & Payments - TradingView
VRDN6389238 Bond Profile — Key Metrics - TradingView
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval - Sahm
Tangible book value per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Total assets of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Price to book ratio of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Operating cash flow per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Total debt per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline - ad-hoc-news.de
Viridian Therapeutics (VRDN) Declines Sharply as Biotech Sector Faces HeadwindsSell Signal Alerts - Bölüm Sonu Canavarı
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - AOL.com
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease - Sahm
Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances - AD HOC NEWS
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone - Yahoo Finance
VRDNViridian Therapeutics Inc Options - Finviz
If You Invested $1,000 in Viridian Therapeutics Inc (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike - Stock Titan
Director Ajer granted 32,341 Viridian Therapeutics (VRDN) stock options at $18.48 - Stock Titan
Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 options at $18.48 - Stock Titan
Fairmount-linked entities receive 32,341 Viridian (VRDN) stock options at $18.48 - Stock Titan
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know - The Globe and Mail
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-07-01 - Seeking Alpha
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30 - Moomoo
VRDN Maintained by Needham -- Price Target Raised to $34.00 - GuruFocus
FDA clears Viridian's veligrotug for TED as Lumvoa - Eyes On Eyecare
Viridian's veligrotug for TED clears FDA as Lumvoa - Eyes On Eyecare
RBC Lifts Price Target on Viridian Therapeutics to $35 From $34, Keeps Outperform, Speculative Risk - Moomoo
VRDN Maintained by RBC Capital -- Price Target Raised to $35.00 - GuruFocus
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says - marketscreener.com
VRDN Maintained by Truist Securities -- Price Target Raised to $38 - GuruFocus
VRDN Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43 - Moomoo
Viridian Therapeutics | SCHEDULE 13G: Others - Moomoo
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval (NASDAQ:VRDN) - Seeking Alpha
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):